Pluri Inc

4DX

Company Profile

  • Business description

    Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.

  • Contact

    MATAM Advanced Technology Park
    Building No. 5
    Haifa3508409
    ISR

    T: +972 747108600

    E: [email protected]

    https://www.pluri-biotech.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    142

Stocks News & Analysis

stocks

Expense concerns for ASX best idea

Expense guidance changes short-term earnings but not long-term fundamentals.
stocks

Chart of the Week: Australian asset managers face structural pressure

Read the latest take from our analysts.
stocks

Going into earnings, is Alphabet a buy, a sell, or fairly valued?

From cloud computing growth to AI monetization, here’s what we’re looking for in Alphabet’s upcoming earnings report.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,181.6061.70-0.67%
CAC 408,066.6886.14-1.06%
DAX 4024,822.7971.65-0.29%
Dow JONES (US)49,015.6012.190.02%
FTSE 10010,154.4353.37-0.52%
HKSE27,826.91699.962.58%
NASDAQ23,857.4540.350.17%
Nikkei 22553,463.71105.000.20%
NZX 50 Index13,342.9969.88-0.52%
S&P 5006,978.030.57-0.01%
S&P/ASX 2008,875.3047.90-0.54%
SSE Composite Index4,151.190.05-0.00%

Market Movers